Post an Analysis Request an analysis AI Londinia analysis
MAAT PHARMA
MAAT PHARMA
- EUR (-)
- 15 min delayed data - Euronext Paris
Open: -
Change: -
Volume: -
Low: -
High: -
High / Low range: -
Type: Stocks
Ticker: MAAT
ISIN: FR0012634822

MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

  • 78

Regulatory News:

MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity contract entered on June 30th, 2023, between Maat Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account:

  • 15,484 shares
  • € 41,285.13
  • Number of executions on buy side on semester: 552
  • Number of executions on sell side on semester: 431
  • Traded volume on buy side on semester: 15,974 shares for € 144,745.75
  • Traded volume on sell side on semester: 12,997 shares for € 122,384.16

As a reminder:

  • the following resources appeared on the last half year statement on December 31st, 2022, on the liquidity account:
  • 12,507 shares
  • € 63,045.61
  • Number of executions on buy side on semester: 390
  • Number of executions on sell side on semester: 330
  • Traded volume on buy side on semester: 14,188 shares for € 131,237.39
  • Traded volume on sell side on semester: 9,342 shares for € 86,141.8
  • the following resources appeared on the liquidity account when the activity started:
    • 0 shares
    • € 200,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

 

Buy side

 

Sell side

 

Number of executions

Number of shares

Traded volume in EUR

 

Number of executions

Number of shares

Traded volume in EUR

Total

552

15,974

144,745.75

431

12,997

122,384.16

02/01/2023

1

1

8.02

4

67

539.35

03/01/2023

1

5

40.00

2

20

161.60

04/01/2023

-

-

-

14

460

3,910.00

05/01/2023

9

281

2,554.29

14

493

4,757.45

06/01/2023

4

88

796.40

-

-

-

09/01/2023

5

261

2,268.09

-

-

-

10/01/2023

2

41

348.50

1

1

8.62

11/01/2023

6

139

1,167.60

2

49

416.50

12/01/2023

8

222

1,847.04

-

-

-

13/01/2023

-

-

-

8

220

1,867.80

16/01/2023

8

200

1,726.00

5

150

1,326.00

17/01/2023

2

60

519.00

2

41

360.80

18/01/2023

2

70

602.00

1

40

348.00

19/01/2023

-

-

-

4

59

522.15

20/01/2023

4

130

1,140.10

4

250

2,250.00

23/01/2023

2

50

424.00

1

30

258.00

24/01/2023

1

1

8.62

4

62

543.74

25/01/2023

5

185

1,650.20

15

499

4,525.93

26/01/2023

4

71

641.13

6

201

1,839.15

27/01/2023

3

60

546.00

2

63

580.86

30/01/2023

1

50

460.00

5

67

623.10

31/01/2023

2

51

464.10

2

51

469.20

01/02/2023

3

101

924.15

4

51

472.26

02/02/2023

4

185

1,652.05

7

300

2,703.00

03/02/2023

-

-

-

21

596

5,673.92

06/02/2023

13

502

4,663.58

4

150

1,440.00

07/02/2023

4

174

1,599.06

1

50

467.00

08/02/2023

20

654

5,886.00

7

300

2,814.00

09/02/2023

8

330

2,880.90

6

152

1,377.12

10/02/2023

5

202

1,801.84

4

140

1,261.40

13/02/2023

7

353

3,014.62

5

180

1,562.40

14/02/2023

3

110

957.00

5

131

1,151.49

15/02/2023

4

112

976.64

3

80

707.20

16/02/2023

3

90

812.70

9

311

2,839.43

17/02/2023

5

61

559.98

1

50

460.00

20/02/2023

3

98

909.44

6

199

1,864.63

21/02/2023

3

73

675.98

3

51

474.30

22/02/2023

4

63

598.50

16

689

6,724.64

23/02/2023

7

144

1,368.00

5

155

1,488.00

24/02/2023

7

215

2,126.35

13

510

5,120.40

27/02/2023

4

100

1,005.00

-

-

-

28/02/2023

3

105

1,033.20

2

106

1,061.06

01/03/2023

4

120

1,207.20

16

1 071

11,288.34

02/03/2023

6

105

1,121.40

-

-

-

03/03/2023

16

450

4,846.50

8

350

3,853.50

06/03/2023

5

184

1,928.32

4

148

1,567.32

07/03/2023

5

76

801.04

4

121

1,291.07

08/03/2023

4

94

1,000.16

3

41

442.80

09/03/2023

17

583

5,853.32

3

30

303.00

10/03/2023

3

60

595.80

-

-

-

13/03/2023

20

730

6,942.30

1

60

576.00

14/03/2023

6

80

765.60

5

160

1,556.80

15/03/2023

6

151

1,449.60

1

1

9.72

16/03/2023

3

51

484.50

3

41

393.60

17/03/2023

5

150

1,438.50

3

64

627.20

20/03/2023

1

40

376.00

1

40

380.00

21/03/2023

4

41

389.50

1

1

9.58

22/03/2023

1

26

247.00

4

146

1,416.20

23/03/2023

2

50

489.00

2

39

384.93

24/03/2023

20

495

4,653.00

4

77

730.73

27/03/2023

14

306

2,836.62

12

369

3,516.57

28/03/2023

3

95

949.05

13

365

3,719.35

29/03/2023

12

330

3,313.20

3

60

621.00

30/03/2023

3

36

355.32

3

70

697.20

31/03/2023

2

51

510.00

6

200

2,054.00

03/04/2023

1

18

180.00

-

-

-

04/04/2023

5

83

830.00

2

6

60.54

05/04/2023

2

70

700.00

1

12

121.20

06/04/2023

2

51

510.00

3

11

111.10

11/04/2023

5

50

500.00

-

-

-

12/04/2023

9

158

1,537.34

3

90

887.40

13/04/2023

7

90

894.60

-

-

-

14/04/2023

7

210

2,037.00

2

50

490.00

17/04/2023

13

375

3,562.50

2

65

624.00

18/04/2023

3

120

1,138.80

3

32

304.32

19/04/2023

2

80

752.00

3

49

465.50

21/04/2023

2

20

190.00

-

-

-

24/04/2023

6

243

2,340.09

10

339

3,328.98

25/04/2023

3

100

977.00

4

160

1,580.80

26/04/2023

1

1

9.72

1

1

9.72

27/04/2023

4

110

1,052.70

-

-

-

28/04/2023

16

528

4,778.40

4

170

1,558.90

02/05/2023

3

50

454.00

-

-

-

03/05/2023

1

1

9.08

1

1

9.08

04/05/2023

9

230

2,017.10

4

19

167.39

05/05/2023

-

-

-

7

92

821.56

08/05/2023

7

146

1,278.96

1

1

8.92

09/05/2023

3

60

522.00

3

50

440.00

10/05/2023

6

214

1,821.14

2

50

440.00

11/05/2023

8

156

1,285.44

3

87

727.32

12/05/2023

1

1

8.28

4

84

709.80

15/05/2023

4

131

1,074.20

4

170

1,434.80

16/05/2023

3

110

936.10

4

100

865.00

17/05/2023

1

40

332.00

-

-

-

19/05/2023

6

354

2,842.62

-

-

-

22/05/2023

1

50

400.00

-

-

-

23/05/2023

5

40

320.00

-

-

-

24/05/2023

1

1

7.98

3

41

328.00

25/05/2023

3

50

400.00

-

-

-

29/05/2023

-

-

-

5

101

828.20

30/05/2023

2

31

251.10

1

1

8.20

31/05/2023

1

50

400.00

-

-

-

01/06/2023

1

1

7.98

1

1

7.98

05/06/2023

2

30

240.00

1

30

243.00

06/06/2023

3

170

1,353.20

1

1

8.20

07/06/2023

3

151

1,182.33

1

1

7.90

08/06/2023

3

91

715.26

1

1

7.90

09/06/2023

4

91

707.07

2

51

402.90

12/06/2023

6

256

1,966.08

3

64

493.44

13/06/2023

2

80

616.00

4

112

873.60

14/06/2023

4

116

886.24

4

67

513.22

15/06/2023

3

140

1,045.80

1

27

202.50

16/06/2023

1

3

22.50

4

80

608.00

19/06/2023

8

282

2,092.44

3

160

1,214.40

21/06/2023

-

-

-

2

60

448.20

22/06/2023

2

70

520.80

-

-

-

23/06/2023

4

101

737.30

3

61

457.50

26/06/2023

1

1

7.28

1

1

7.28

27/06/2023

-

-

-

1

20

148.00

28/06/2023

5

194

1,402.62

-

-

-

29/06/2023

4

203

1,467.69

-

-

-

30/06/2023

1

30

216.00

-

-

-

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230713567556/en/

Business Wire
Business Wire
Business Wire, acquired by Berkshire Hathaway in 2006, is the global market leader in commercial news distribution. Thousands of member companies and organizations depend on Business Wire to transmit their full-text press releases, regulatory filings, photos and other multimedia content to journalists, financial professionals, investor services, regulatory authorities and consumers worldwide.
NEW !